Macquarie Group Ltd. acquired a new position in Medifast Inc (NYSE:MED) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 4,500 shares of the specialty retailer’s stock, valued at approximately $267,000.

Several other institutional investors have also modified their holdings of the stock. Acrospire Investment Management LLC bought a new stake in Medifast during the second quarter valued at $108,000. Sei Investments Co. boosted its position in Medifast by 95.9% during the second quarter. Sei Investments Co. now owns 3,922 shares of the specialty retailer’s stock valued at $163,000 after acquiring an additional 1,920 shares during the last quarter. BNP Paribas Arbitrage SA boosted its position in Medifast by 86.2% during the second quarter. BNP Paribas Arbitrage SA now owns 4,189 shares of the specialty retailer’s stock valued at $174,000 after acquiring an additional 1,939 shares during the last quarter. AHL Partners LLP bought a new stake in Medifast during the second quarter valued at $241,000. Finally, Municipal Employees Retirement System of Michigan boosted its position in Medifast by 28.8% during the third quarter. Municipal Employees Retirement System of Michigan now owns 5,910 shares of the specialty retailer’s stock valued at $351,000 after acquiring an additional 1,320 shares during the last quarter. 86.91% of the stock is currently owned by institutional investors.

In other news, Director Glenn W. Welling sold 250,000 shares of the company’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $65.00, for a total transaction of $16,250,000.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Glenn W. Welling sold 275,000 shares of the company’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $64.60, for a total transaction of $17,765,000.00. The disclosure for this sale can be found here. Insiders have sold 550,000 shares of company stock worth $34,019,500 in the last quarter. Company insiders own 5.40% of the company’s stock.

A number of brokerages have commented on MED. DA Davidson upped their price target on shares of Medifast to $89.00 and gave the company a “buy” rating in a research report on Friday, December 8th. Zacks Investment Research raised shares of Medifast from a “hold” rating to a “buy” rating and set a $79.00 price target on the stock in a research report on Friday, November 10th. ValuEngine cut shares of Medifast from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Finally, Sidoti reaffirmed a “neutral” rating and set a $55.00 price target (up previously from $49.00) on shares of Medifast in a research report on Thursday, September 21st. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $74.33.

Shares of Medifast Inc (NYSE MED) opened at $73.46 on Tuesday. The company has a market cap of $877.36, a price-to-earnings ratio of 36.22, a price-to-earnings-growth ratio of 2.26 and a beta of 0.51. Medifast Inc has a 1 year low of $40.00 and a 1 year high of $74.38.

Medifast (NYSE:MED) last issued its quarterly earnings results on Tuesday, November 7th. The specialty retailer reported $0.55 EPS for the quarter, beating the Zacks’ consensus estimate of $0.51 by $0.04. The business had revenue of $77.20 million for the quarter, compared to analysts’ expectations of $74.94 million. Medifast had a net margin of 8.58% and a return on equity of 24.07%. The business’s quarterly revenue was up 12.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.51 earnings per share. equities analysts predict that Medifast Inc will post 2.17 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, February 8th. Stockholders of record on Friday, December 22nd will be issued a dividend of $0.48 per share. The ex-dividend date of this dividend is Thursday, December 21st. This represents a $1.92 annualized dividend and a dividend yield of 2.61%. This is a positive change from Medifast’s previous quarterly dividend of $0.32. Medifast’s dividend payout ratio is currently 63.05%.

COPYRIGHT VIOLATION WARNING: This report was originally published by Watch List News and is the property of of Watch List News. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://www.watchlistnews.com/4500-shares-in-medifast-inc-med-acquired-by-macquarie-group-ltd/1772654.html.

Medifast Company Profile

Medifast, Inc produces, distributes and sells weight loss, weight management, and healthy living products, and other consumable health and nutritional products. The Company’s product lines include weight loss, weight management, and healthy living meal replacements, snacks, hydration products, and vitamins.

Want to see what other hedge funds are holding MED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medifast Inc (NYSE:MED).

Institutional Ownership by Quarter for Medifast (NYSE:MED)

Receive News & Ratings for Medifast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medifast and related companies with MarketBeat.com's FREE daily email newsletter.